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BACKGROUND: Generally ameloblastoma is a locally aggressive, slow growing, non-metastatic epithelial odontogenic benign tumor. However, 
rarely some ameloblastoma can metastasize in spite of a 
benign histologic appearance. Targeting ameloblastoma 
by inducing it into apoptosis could be a beneficial strategy, 
since many ameloblastoma cases were reported recurrent 
after surgical therapy.
CONTENT: To investigate ameloblastoma in cellular 
aspect, cytological pattern of ameloblastoma was divided 
into outer layer/peripheral and inner layer/central cells. 
Tumor necrosis factor (TNF)-α, Fas ligand (FasL), TNF 
receptor (TNFR)1/death receptor (DR)1, TNFR2/DR2, 
DR4, DR5 and Fas were highly expressed in central than 
peripheral cells. Despite inducing apoptosis, TNF-α can 
induce PI3K leading to Akt and p44/42 mitogen-activated 
protein kinases (MAPK) activation in AM-1 cells, which 
later induce cell survival and proliferation. Therefore 
apoptotic induction in ameloblastoma should be suggested 
in higher TNF-α concentration.  Expression of FasL and 
Fas are closely associated with squamous metaplasia and 
granular transformation of the tumor cells, suggesting 
that apoptosis induced by FasL may play a role in the 
terminally differentiated or degenerative ameloblastoma 
cells. TNF-related apoptosis-inducing ligand (TRAIL) has 
emerged as an apoptotic inducing anticancer agent in tumor 
cells specifically. TRAIL induced activation of caspases, 
lowering mitochondrial membrane potential, high number 
of apoptotic cells in ameloblastoma cells. Therefore, TRAIL 
could be a potential agent for targeting ameloblastoma, 
although further study should be explored.
SUMMARY: Targeting ameloblastoma by inducing it into 
apoptosis could be achieved effectively, although some 
criteria should be considered. Therefore understanding the 
underlying apoptosis signaling pathways are necessary 
for inducing ameloblasotma into apoptosis. Investigations 
on other apoptosis-related molecules, potential apoptosis-
inducing natural products, and novel approach in 
reprogramming, are important in the future for a better 
management of ameloblastoma.
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Abstract
Introduction
Generally ameloblastoma is a locally aggressive, slow 
growing, non-metastatic epithelial odontogenic benign 
tumor.(1,2) However, rarely some ameloblastoma can 
metastasize in spite of a benign histologic appearance.(3,4) 
Ameloblastoma  has several  histopathologic  patterns, 
including follicular, plexiform, desmoplastic, basal cell, 
acanthomatous, desmoplastic and granular cell. While 
clinically ameloblastoma is classified into solid, cystic and 
peripheral.(4) 
 To investigate ameloblastoma in cellular aspect, 
cytological pattern of ameloblastoma was divided into outer 
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layer/peripheral and inner layer/central cells.(3,5-13) The 
peripheral cells were further classified into basal, columnar 
and cuboidal cell types.(5,7,8,10) Immunohistochemical 
studies have shown that B cell lymphoma (Bcl)-2 (3,5,7), 
Bcl-x (3,6) proliferating cell nuclear antigen (PCNA) 
(5), Ki-67 (5), murine double minute 2 (MDM2) (8,9), 
Midkine (10) and protein (p)65 nuclear factor (NF) kB (13) 
were highly expressed in peripheral than in central cells. 
Meanwhile, tumor necrosis factor (TNF)-α (11), Fas ligand 
(FasL) (14), TNF receptor (TNFR)1/death receptor (DR)1 
(11), TNFR2/DR2 (11), DR4 (12), DR5 (12) and Fas (14) 
were highly expressed in central than peripheral cells. 
 In accordance with the expressions of apoptotic 
ligand and receptor in central cells, expressions of p53 
(8,15), phosphatase and tensin homolog (PTEN) (16), 
phosphorylated-PTEN  (16),  phosphorylated-Jun N-terminal 
kinase (JNK) (17), Bcl-2 associated X protein (Bax) (3,6), 
Bcl-2 homologous antagonist killer (Bak) (3,5,7), caspase 
9 (18), apoptotic protease activating factor-1 (APAF-1) 
(18), caspase 3 (19), terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) (14,20) were observed 
in central cells as well. Hence, some reports suggested that 
central cells have higher apoptotic activity than peripheral 
cells.(3,6,14,20) Targeting ameloblastoma by inducing it 
into apoptosis could be a beneficial strategy, since many 




TNF-α is mainly produced by macrophages and monocytes. 
TNF-α plays important roles in cell proliferation, apoptosis, 
survival and differentiation.(11,21) TNF-α depends on 
its concentration might induce different mechanisms: 
a low concentration  of  TNF-α  mainly  induces 
phosphatidylinositol-3-OH kinase  (PI3K)/Akt/inhibitor of 
kB (IkB) kinase (IKK)/IkB survival signaling pathway.(21) 
Meanwhile, a high concentration of TNF-α mainly induces 
apoptosis.(21) Inhibition of low concentration of TNF-
α-induced survival signaling pathway with wortmannin, 
LY294002, kinase negative (KN)-Akt, KN-IKK-α, KN-
IKK-β or undegradable IκB (undeg-IκB), will turn low 
concentration TNF-α to induce apoptosis (Figure 1).(21) 
KN DNA constructs including KN-Akt, KN-IKK-α and 
KN-IKK-β, were generated as mutated competitive agents 
having defected kinase function.(21) Meanwhile, undeg-
IκB was generated as competitive agent with mutated 
phosphorylation site. Hence, IκB will not be labeled for 
degradation.(21)
 TNF-α, TNF Receptor (TNFR)1 and TNFR2, are 
expressed in AM-1 cells and ameloblastoma.(11) AM-1 
cells, a cell line of ameloblastoma, have been widely used 
as ameloblastoma cell model.(8-13,22) Despite inducing 
apoptosis, 1-100 ng/mL TNF-α can induce PI3K leading to 
Akt and p44/42 mitogen-activated protein kinases (MAPK) 
activation in AM-1 cells, which later induce cell survival 
and proliferation.(11) Therefore apoptotic induction in 
ameloblastoma should be suggested in higher TNF-α 
concentration.
FasL
FasL, a cell-surface molecule belonging to TNF family, 
binds  to  its  receptor  Fas,  a  member  of  the  TNFR 
family. The binding triggers a series of intracellular signal 
transduction leading  to  the  activation  of  caspases. 
Activated-caspases execute  the  apoptotic  process  by 
cleaving  various  substrates.(14) Expression of FasL 
and Fas was detected in the majority of ameloblastomas. 
A strong staining was observed in the central area of 
tumor islands. Close association was reported between 
the expression of FasL-Fas and squamous metaplasia / 
granular transformation of the tumor cells. This suggest that 
apoptosis induced by FasL may play a role in the terminally 
differentiated or degenerative  ameloblastoma  cells.(15) 
Hence  targeting  Fas   for   ameloblastoma   apoptotic 
induction  could  be  more suitable for more differentiated 
types of ameloblastoma, such as plexiform or follicular, but 
not basal cell type.
TNF-related Apoptosis-inducing Ligand (TRAIL)
TRAIL, a potent ligand in inducing apoptosis, has emerged 
as an apoptotic inducing anticancer agent in tumor cells 
specifically. Due to its activity on ameloblastoma, an 
investigation has been reported.(12) Expressions of 
DR4 and DR5, TRAIL's receptors, were detected in all 
ameloblastoma types and AM-1 cells. By applying TRAIL 
in AM-1 cells for 24 hours, cleavages of caspase-8, -9 and 
-3 were formed (Figure 1).(12) Induction of mitochondrial 
apoptotic pathway was confirmed, marked by lowering 
mitochondrial membrane potential. High number of 
apoptotic cells were noticed in AM-1 cells upon treatment of 
TRAIL for 24 hours.(12) Hence TRAIL could be a potential 
agent for targeting ameloblastoma, although further study 
should be explored to confirm this evidence. In addition, 
Osteoprotegerin (OPG), an inhibitor should be avoided 
when the TRAIL was suggested as the targeting agent.
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Figure 1. Apoptosis signaling pathway in ameloblastoma. Several major pathways have been clarified and shown to be effective to 
induce apoptosis in ameloblastoma. AP-1: Activator protein-1; DD: Death Domain; DR: Death Receptor; Cyto-C: Cytochrome-C; t-Bid: 
truncated B cell lymphoma (Bcl)-2 homology (BH)3 interacting-domain death agonist.
 OPG has been reported as a useful receptor to inhibit 
Receptor Activator of NFkB Ligand (RANKL) in inducing 
osteoclastogenesis.(22) Expression of OPG was observed in 
AM-1 cells and ameloblastoma. Since OPG was shown to 
bind with TRAIL as well, in an apoptotic assay with AM-1 
cells, OPG could suppress TRAIL's capacity in inducing 
apoptosis.(23) Therefore, osteoclastogenesis suppression 
using OPG on ameloblastoma-mediating-bone destruction 
should be considered, since the OPG can also suppress 
TRAIL’s  function  in  inducing  apoptosis  in  ameloblastoma.
Apoptosis-related Secondary Messengers
p53/MDM2
The p53 protein, known as a potent cell growth inhibitor, 
is responsible for arresting the cell cycle at several 
distinct points, as well as activating the apoptotic signal 
transduction in some circumstances.(8) Cellular stresses 
can activate p53, including DNA damage and hypoxia. 
Investigation in ameloblastoma has shown that most of wild 
type p53 population was detected in ameloblastoma but the 
p53 labeling indices were not correlated neither with WHO 
classification nor the cytological pattern of the outer layer 
cells of ameloblastoma.(8) 
 MDM2 can modulate tumor suppressor activity of p53 
and mediate degradation of p53. The degradation of p53 can 
be triggered by shuttling p53 from nucleus to cytoplasm. 
MDM2 was detected and correlated with cytological pattern 
of the outer layer cells of ameloblastoma. Hence, p53 in 
ameloblastoma might have a function in the cell cycle, 
however p53 suppressor activity might be suppressed by 
MDM2.(8,9) Therefore, a strategy in inhibiting MDM2 
could be suggested and explored further to regain p53's role 
as cell growth inhibitor or apoptosis activator.
PI3K/Akt/Mammalian-target of Rapamycin (mTOR)
In carcinogenesis, loss of PTEN allows the over-activated 
PI3K/Akt pathway in inducing its downstream. This 
pathway allows acceleration of proliferation, inhibition of 
apoptosis and deregulation of cell cycle. An allelic loss of 
PTEN was reported to be occurred in ameloblastomas.(16) 
The aberrant expression of PTEN in ameloblastomas was 
reported to be correlated with the inherent aggressiveness of 
ameloblastoma.(16)
 In the study using AM-1 cells, as mentioned earlier, 
the phosphorylation of Akt (Ser473) could be induced by 
TNF-α. Akt phosphorylation is usually associated with cell 
survival. Therefore, in ameloblatoma, Akt phosphorylation 
should be inhibited and the attempt can be achieved by 
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pretreatment of LY294002, a PI3K inhibitor.(11) Besides 
TNF-α, a protein expressed during tooth development in 
the epithelium of the odontogenic apparatus or its remnant 
tissues called Midkine, could induce phosphorylation of 
Akt (Ser473) and Thr308.(10) These results support some 
explanation regarding how remnant tissues can potentially 
develop into ameloblastoma. Targeting Akt signaling 
pathway in a PTEN-loss scheme can be suggested by using 
PI3K inhibitor, such as LY294002, wortmannin, or other 
equal inhibitors (Figure 1).
 
p42/44 MAPK
Some studies have shown the effects of MAPK inducers 
in ameloblastomas. Besides playing a critical role in cell 
proliferation, MAPK plays a role in cell survival as well. 
TNFα induced phosphorylation of p44/42 mitogen-activated 
protein kinase (MAPK) (Thr202/Tyr204) in AM-1 cells.(11) 
The phosphorylation can later be inhibited by pretreatment 
of U0126, mitogen-activated extracellular-regulated kinase 
(MEK) 1/2 inhibitor.(24) Therefore apoptosis induction in 
ameloblastoma can be achieved, besides applying higher 
TNF-α concentration, a MEK 1/2 inhibitor, such as U0126 
or other equal inhibitors, could be suggested (Figure 1).Future Research Perspective
Major targets have been reported to induce ameloblastoma 
into apoptosis as described above. Other second messengers, 
such as Bcl-2 family (3,6), Survivin (15,25), APAF-1 (18), 
X chromosome-linked inhibitor of apoptosis protein (XIAP) 
have been reported, but there was not any functional study 
related to these molecules.(25) Therefore those molecules 
should be further investigated, so that a more complete 
strategy in inducing ameloblastoma into apoptosis could be 
obtained. 
 Due to apoptotic induction, as a substitute for 
chemicals, natural products have been proposed to avoid 
possible side effects caused. There are studies of herbal 
extracts in targeting cancer cells, such as caffeic acid (26), 
artocarpin (27), Curcuma mangga (28), Kleinhovia hospita 
L. (29), Kayu Secang (30), Piper betle L. (28), Catharanthus 
roseus [L] G.Don (28), Dendrophtoe petandra L. (28,31), 
Nephelium lappaceum L. (28), Curcuma mangga Val. (28), 
Brucea javanica (31,32), Artocarpus altilis (33,34), Piper 
crocatum Ruiz & Pav (35) and prenylated flavonoids (36). 
These potential extracts should be further investigated on 
ameloblasotoma.
 Research in cancer cells genetic modification has 
been started and shown as a potential approach in managing 
cancer. Cell reprogramming for turning differentiated 
cells into stem cells has became a trending technology.
(37) In cancer research, reversing the breast cancer stem 
cell into breast somatic stem cell has been reported.(38) 
The reprogramming/reversing could be conducted with a 
single gene or series of genes modifications. Or simply by 
changing the microenvironment, as being conducted in stem 
cell research for differentiating stem cell.(39) Meanwhile, 
in cancer research, modification on the microenvironment 
has also been reported.(40) Therefore, this potential strategy 
should be further investigated on ameloblastoma as well.
Conclusion
Targeting ameloblastoma by inducing it into apoptosis could 
be achieved effectively, although some criteria should be 
considered. Not only apoptosis-inducing ligand, but second 
messengers also play crucial role in apoptotic induction. 
Therefore understanding the underlying apoptosis signaling 
pathways are necessary for inducing ameloblasotma 
into apoptosis. Investigations on other apoptosis-related 
molecules, potential apoptosis-inducing natural products, 
and novel approach in reprogramming, are important in the 
future for a better management of ameloblastoma.
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